The Oncologist

12/03/2026

Patients with metastatic **alCancer with a pathological complete response (pCR) at the primary tumor after preop therapy have favorable long-term outcomes: 62.2% 2️⃣-year PFS and 84.5% 3️⃣-year OS. Those with colon CA showed esp. strong survival trends vs re**al CA.
https://doi.org/10.1093/oncolo/oyag025

10/03/2026

HER2-targeted therapies are not standard treatment for non-breast solid tumors currently. Results of this study provided pyrotinib as a potential treatment option for later-line therapy of HER2-positive solid tumors, especially colore**al cancer.

AbstractBackground. Amplification/overexpression of the human epidermal growth factor receptor 2 (HER2) gene drives cell proliferation, differentiation, an

09/03/2026

An asynchronous electronic consent for improving consent in research among patients with cancer
https://doi.org/10.1093/oncolo/oyaf326

06/03/2026

Neoadjuvant endocrine therapy plus CDK4/6 inhibitors shows similar response rates to standard chemotherapy in HR-positive locally advanced and may benefit chemo-insensitive tumors with improved tumor shrinkage and biologic markers.

AbstractBackground. Neoadjuvant treatment for hormone receptor (HR)-positive breast cancer remains limited, particularly for tumors that are insensitive to

05/03/2026

New research finds patients treated with immune checkpoint inhibitors (ICIs) show ⬆️ decline in psoas muscle density compared with those not on ICIs, independent of kidney function, highlighting potential muscle-related effects of .

AbstractBackground. The association between skeletal muscle wasting and immune checkpoint inhibitor (ICI) use for cancer and whether pre–treatment kidney f

03/03/2026

Dr. Kleinhenz et al describe a case of treatment of FGFR2 fusion-positive biliary tract cancer with lenvatinib after progression on pemigatinib and futibatinib.
https://doi.org/10.1093/oncolo/oyaf322

02/03/2026

New review: A multidisciplinary team (MDT) approach is 🔑 in supporting personalized decision-making in well-differentiated . As diagnostics, molecular tools, and systemic options expand, coordinated care improves risk-adapted management.

AbstractBackground. The incidence of thyroid cancer has increased markedly in recent years, largely driven by well-differentiated thyroid carcinoma (WDTC).

27/02/2026

In a multicenter real-world study, combining ✚ PD-1 inhibitors significantly improved tumor control and long-term survival vs SBRT alone in unresectable hepatocellular carcinoma (HCC), with manageable toxicity and no major increase in severe adverse events.

AbstractBackground. Radiotherapy (RT) provides meaningful local control for hepatocellular carcinoma (HCC) but is limited by radio-resistance. Preclinical

26/02/2026

BEVATOMOX Phase II: Raltitrexed + oxaliplatin (TOMOX) + bevacizumab showed comparable efficacy and safety to standard mFOLFOX6 + bevacizumab in second-line metastatic **alCancer, offering a potential alternative regimen.

AbstractBackground. Second-line FOLFOX-bevacizumab treatment is effective in metastatic colore**al cancer (mCRC) treatment after irinotecan-based chemother

25/02/2026

The QuICC trial tested a quadruple regimen in mismatch repair–proficient metastatic **alCancer, showing that combining multiple immune agents can elicit clinical activity in tumors traditionally resistant to immunotherapy.
https://doi.org/10.1093/oncolo/oyag008

23/02/2026

Network meta-analysis in RAS wild-type metastatic **alCancer: triplet chemo + anti-EGFR improves response vs chemo alone, but no clear survival advantage over other targeted combinations. Careful patient selection remains key due to increased toxicity.
https://doi.org/10.1093/oncolo/oyag011

20/02/2026

In this largest real-world cohort of metastatic to date, the clinical benefit and manageable safety of sacituzumab govitecan seen in the ASCENT trial was confirmed in routine practice. Notably, poor performance status and liver metastases predicted inferior outcomes.

AbstractBackground. Sacituzumab govitecan (SG), an antibody–drug conjugate targeting TROP-2, demonstrated superior efficacy over standard chemotherapy in h